Drugs / EZN-4176
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01337518 | Mar 2011 → Dec 2013 | prostate neoplasm | Enzon Pharmaceuticals, Inc. | Suspended | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EZN-4176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01337518 ↗ |
| Action | Inhibit | “an Androgen Receptor mRNA Antagonist” NCT01337518 ↗ |
| Route | Intravenous | “EZN-4176 can be administered as a weekly one-hour i.v. infusion” NCT01337518 ↗ |
| Target | AR | “an Androgen Receptor mRNA Antagonist” NCT01337518 ↗ |